Drugs / Fibrinogen
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02281500 | Jul 2016 → Nov 2019 | congenital afibrinogenemia | Grifols Therapeutics LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00968045 | Apr 2009 → Feb 2012 | coronary artery disorder, hemorrhagic disease | Sahlgrenska University Hospital | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT01359878 | May 2011 → May 2013 | — | Copenhagen University Hospital at Herlev | Completed | Missed primary |
| Phase 33 trials · 1 missed | ||||||
| Phase 3 | NCT05300672 | Feb 2022 → Dec 2024 | intracerebral hemorrhage, ischemic stroke | Azienda Usl di Bologna | Completed | No outcome recorded |
| Phase 3 | NCT01662856 | Aug 2012 → Dec 2015 | vascular hemostatic disease | Grifols, S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01539057 | Jul 2012 → Sep 2013 | esophageal varices with bleeding | Hospital Universitari de Bellvitge | Unknown | Missed primary |
| Phase 44 trials | ||||||
| Phase 4 | NCT05391412 | Jun 2022 → Jul 2023 | disseminated intravascular coagulation, hemorrhagic disease, scoliosis | Brno University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04376762 | Oct 2021 → Mar 2023 | hemorrhagic disease, juvenile Huntington disease | University of Virginia | Completed | No outcome recorded |
| Phase 4 | NCT04405518 | Jun 2019 → Nov 2021 | fibrinolytic defect | Antoni Sabaté Pes | Unknown | No outcome recorded |
| Phase 4 | NCT02299947 | Aug 2014 → Apr 2018 | hemorrhagic disease, thoracic aortic aneurysm | St. Antonius Hospital | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00713596 | Jul 2008 → Jan 2010 | — | Mayo Clinic | Terminated | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 1/2 | NCT02203968 Comparator | Oct 2014 → Dec 2015 | blood coagulation disease, hemorrhagic disease | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 1/2 | NCT00493272 Comparator | Jun 2007 → Apr 2008 | blood coagulation disease | Christian Fenger-Eriksen | Completed | No outcome recorded |
| Phase 2 | NCT02344069 Comparator | Feb 2015 → Mar 2017 | hemorrhagic disease | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 3 | NCT01623531 Comparator | Feb 2014 → Mar 2019 | cardiac valvular defect | Nova Scotia Health Authority | Completed | No outcome recorded |
| Phase 3 | NCT01471730 Comparator | Nov 2011 → Dec 2014 | heart disorder | IRCCS Policlinico S. Donato | Completed | No outcome recorded |
Press releases naming this drug 12 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fibrinogen | “Combination of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).” NCT01662856 ↗15“single dose fibrinogen concentrate immediately after CTC leads to a decrease in the number of allogenic blood transfusions” NCT02299947 ↗ |
| Known as | Riastap | “The drug used in this study is Riastap, 1g (Fibrinogen).” NCT04405518 ↗ |
| Action | Restore | “Use of fibrinogen concentrate allows high-dose substitution without the need for blood type crossmatch.” PMID 22805300 ↗ Jul 2012 |
| Modality | Protein / enzyme biologic | “fibrinogen concentrate” NCT00493272 ↗ |
| Route | Intravenous | “2 g of fibrinogen concentrate (Haemocomplettan, CSL Behring) i.v.” NCT01359878 ↗ |